Heterogeneity of drug target expression among metastatic lesions: lessons from a breast cancer autopsy program.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed.

1. Tumor heterogeneity and clinically invisible micrometastases in metastatic breast cancer-a call for enhanced surveillance strategies.NPJ precision oncology · 2024
   Article
2. Long-chain fatty acyl coenzyme A inhibits NME1/2 and regulates cancer metastasis.Proceedings of the National Academy of Sciences of the United States of America · 2022
   Article
3. NDK/NME proteins: a host-pathogen interface perspective towards therapeutics.Current genetics · 2022
   Review
4. The lingering mysteries of metastatic recurrence in breast cancer.British journal of cancer · 2021
   Review
5. MDA-9/Syntenin (SDCBP): Novel gene and therapeutic target for cancer metastasis.Pharmacological research · 2020
   Review
6. The NDPK/NME superfamily: state of the art.Laboratory investigation; a journal of technical methods and pathology · 2018
   Article
7. Comparison of immunophenotypes of primary breast carcinomas and multiple corresponding distant metastases: an autopsy study of 25 patients.Clinical & experimental metastasis · 2017
   Article
8. Tumor cell dissemination: emerging biological insights from animal models and cancer patients.Cancer cell · 2013
   Review
9. On the origin of cancer metastasis.Critical reviews in oncogenesis · 2013
   Review
10. Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012
    Article
11. Perspectives on the mesenchymal origin of metastatic cancer.Cancer metastasis reviews · 2010
    Review
12. Cancer metastasis as a therapeutic target.European journal of cancer (Oxford, England : 1990) · 2010
    Review
13. Targeting activated integrin alphavbeta3 with patient-derived antibodies impacts late-stage multiorgan metastasis.Clinical & experimental metastasis · 2010
    Article
14. Cancer as a metabolic disease.Nutrition & metabolism · 2010
    Article
15. Convergence of biomarkers, bioinformatics and nanotechnology for individualized cancer treatment.Trends in biotechnology · 2009
    Review
16. Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2009
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as